Taro Pharmaceutical Industries Ltd (TARO)
42.32
-0.10
(-0.24%)
USD |
NYSE |
May 08, 16:00
42.32
0.00 (0.00%)
After-Hours: 20:00
Taro Pharmaceutical Industries Enterprise Value: 692.12M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 07, 2024 | 692.12M |
May 06, 2024 | 694.38M |
May 03, 2024 | 693.25M |
May 02, 2024 | 695.51M |
May 01, 2024 | 691.00M |
April 30, 2024 | 694.38M |
April 29, 2024 | 694.38M |
April 26, 2024 | 691.37M |
April 25, 2024 | 694.38M |
April 24, 2024 | 683.85M |
April 23, 2024 | 684.98M |
April 22, 2024 | 686.11M |
April 19, 2024 | 685.73M |
April 18, 2024 | 683.48M |
April 17, 2024 | 685.36M |
April 16, 2024 | 678.22M |
April 15, 2024 | 680.85M |
April 12, 2024 | 677.84M |
April 11, 2024 | 681.22M |
April 10, 2024 | 677.84M |
April 09, 2024 | 683.48M |
April 08, 2024 | 677.46M |
April 05, 2024 | 681.22M |
April 04, 2024 | 681.22M |
April 03, 2024 | 687.61M |
Date | Value |
---|---|
April 02, 2024 | 681.22M |
April 01, 2024 | 684.98M |
March 28, 2024 | 689.12M |
March 27, 2024 | 686.11M |
March 26, 2024 | 681.60M |
March 25, 2024 | 685.36M |
March 22, 2024 | 679.72M |
March 21, 2024 | 683.48M |
March 20, 2024 | 688.74M |
March 19, 2024 | 680.85M |
March 18, 2024 | 674.08M |
March 15, 2024 | 681.60M |
March 14, 2024 | 680.10M |
March 13, 2024 | 681.60M |
March 12, 2024 | 675.21M |
March 11, 2024 | 677.46M |
March 08, 2024 | 677.46M |
March 07, 2024 | 680.85M |
March 06, 2024 | 637.63M |
March 05, 2024 | 674.83M |
March 04, 2024 | 678.22M |
March 01, 2024 | 680.10M |
February 29, 2024 | 678.97M |
February 28, 2024 | 675.59M |
February 27, 2024 | 681.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
24.95M
Minimum
Mar 28 2023
3.049B
Maximum
May 09 2019
1.146B
Average
1.073B
Median
Enterprise Value Benchmarks
InspireMD Inc | 10.70M |
BiomX Inc | 18.37M |
Alpha Tau Medical Ltd | 94.52M |
Pluri Inc | 26.73M |
Holdco Nuvo Group DG Ltd | -- |
Enterprise Value Related Metrics
Net Income (Quarterly) | 20.21M |
Revenue (Quarterly) | 157.14M |
Total Expenses (Quarterly) | 141.26M |
EPS Diluted (Quarterly) | 0.54 |
Gross Profit Margin (Quarterly) | 50.83% |
Profit Margin (Quarterly) | 12.86% |
Earnings Yield | 2.88% |
Operating Earnings Yield | 1.38% |
Normalized Earnings Yield | 2.878 |